Eric Peter van der Veer

Chief Scientific Officer

Hybridize Therapeutics


Born and raised just outside of Toronto (Canada), Eric’s Dutch roots led him study Chemistry at the University of Amsterdam (M.Sc). His Canadian roots led him to return to Canada to pursue a Ph.D. degree in Biochemistry at the University of Western Ontario (London, Canada). He returned to the Netherlands (LUMC) and started his own research group specializing in RNA biology of healthy and diseased cells, yielding publications in Nature Communications, European Heart Journal and Circulation Research. For his work, he was awarded the Irvine H. Page Award by the American Heart Association.

In 2015, he discovered a novel means of targeting the BK virus, a virus that is highly problematic in kidney transplantation and allogeneic stem cell transplantation patients. To further develop this concept and transition the technology to the clinic, he left the LUMC in 2019 and founded Hybridize Therapeutics. Today, Hybridize Therapeutics is a company focused on helping patients suffering from kidney diseases with RNA-based therapies.